Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.
Authors
Rajendram, RTaylor, P
Wilson, V
Harris, N
Morris, O
Tomlinson, M
Yarrow, S
Garrott, H
Herbert, H
Dick, A
Cook, A
Gattamaneni, Rao
Jain, R
Olver, J
Hurel, S
Bremner, F
Drummond, S
Kemp, E
Ritchie, D
Rumsey, N
Morris, D
Lane, C
Palaniappan, N
Li, C
Pell, J
Hills, R
Ezra, D
Potts, M
Jackson, S
Rose, G
Plowman, N
Bunce, C
Uddin, J
Lee, R
Dayan, C
Affiliation
Moorfields Eye Hospital NHS Foundation Trust, London, UKIssue Date
2018-01-30
Metadata
Show full item recordAbstract
Standard treatment for thyroid eye disease is with systemic corticosteroids. We aimed to establish whether orbital radiotherapy or antiproliferative immunosuppression would confer any additional benefit.Citation
Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. 2018, Lancet Diabetes EndocrinolJournal
The Lancet, Diabetes & EndocrinologyDOI
10.1016/S2213-8587(18)30021-4PubMed ID
29396245Type
ArticleLanguage
enISSN
2213-8595ae974a485f413a2113503eed53cd6c53
10.1016/S2213-8587(18)30021-4
Scopus Count
Collections
Related articles
- Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
- Authors: Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ
- Issue date: 2021 Jun
- Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
- Authors: Kahaly GJ, Riedl M, König J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Führer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marinò M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM, European Group on Graves' Orbitopathy (EUGOGO).
- Issue date: 2018 Apr
- Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
- Authors: Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK
- Issue date: 2015 Oct 24
- Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.
- Authors: Glover M, Smerdon GR, Andreyev HJ, Benton BE, Bothma P, Firth O, Gothard L, Harrison J, Ignatescu M, Laden G, Martin S, Maynard L, McCann D, Penny CEL, Phillips S, Sharp G, Yarnold J
- Issue date: 2016 Feb
- Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial.
- Authors: Rajendram R, Lee RW, Potts MJ, Rose GE, Jain R, Olver JM, Bremner F, Hurel S, Cook A, Gattamaneni R, Tomlinson M, Plowman N, Bunce C, Hollinghurst SP, Kingston L, Jackson S, Dick AD, Rumsey N, Morris OC, Dayan CM, Uddin JM
- Issue date: 2008 Jan 31